This trial is evaluating whether Atezolizumab will improve 1 primary outcome and 2 secondary outcomes in patients with Cancer of Colon. Measurement will happen over the course of Up to 30 days after last treatment.
This trial requires 700 total participants across 2 different treatment groups
This trial involves 2 different treatments. Atezolizumab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
Atezolizumab was well tolerated, but the side effects of the drug were consistent with the known properties of monoclonal antibodies and included fatigue, weight loss, and infections.
The safety of atezolizumab was evaluated in 929 people with stage III or IV CRC. Tumor shrinkage was seen in 97% of patients (100% with TGF beta R-expressing tumors). Serious adverse events were rare (4%) in the overall group, but were more common (7%) in the atezolizumab group.
Most patients are receiving and in the treatment of cancer of colon. Patients are receiving chemotherapy and/or radiotherapy the majority of the time. In fact, most patients still receive no therapy before surgery. The data from this study are the same as [Power(http://www.withpower.com/clinical-trials/cancer-of-colon) and [SIGECARE-BIOTAGE] [Kanaka and Hegazy, Clin. Oncol.]]. The goal of this study is find out which treatments are not being provided for those patients who are not receiving treatment. Clin. Oncol. (2016).
Hereditary factors are a key factor in familial colon cancer. Identifying and following these families may decrease the risk of colon cancer. Furthermore, colorectal neoplasm can be a potential clue for the development of new biomarkers.
Current data indicate that the prevalence of colon cancer is increasing at a rate two to three times higher than that of the general US population.
Colorectal cancer is the leading nonprostate cancer among women, among men, and in all races combined. Among men, colorectal cancer accounts for more deaths from cancer than any other cancer.
Signs of cancer of colons are not all obvious. Patients may have signs unrelated to the presence of CRC, such as weight loss, change in bowel habits or tiredness. The diagnosis of cancer of colons needs a high index of suspicion from doctors who are aware of appropriate examinations, examinations and test results.
Current medical therapies, including drugs and surgery, are effective for the prevention and treatment of colon cancer. The main drawback is that it may return even with proper treatment. However, it can be eliminated by removing the cause, namely, lifestyle modifications such as nutritional deficiencies, smoking, low-grade inflammation, and a high-fat diet, including red meats.
Results from a recent paper of our study suggest that patients should be informed about the average age at which colon cancer is expected to occur, and how much time elapsed between the onset of symptoms and medical attention.
The majority of atezolizumab treated, metastatic UC patients with ECOG >2 received a first line atezolizumab treatment that included chemotherapy (83.3%) or chemotherapy and surgery (12.0%). Overall, 18% of patients receiving atezolizumab treatment received a second-line treatment.
The major risk of [colon cancer](https://www.withpower.com/clinical-trials/colon-cancer) is colon cancer and not a subtype of cancer, i.e. rectal cancer. The major risk to rectum cancers is recurrence and not stage or subtype. Colon cancer is not a lethal disease.
Of the 3,100 patients enrolled, there were 740 patients (23.5%) in whom colon cancer spread to the liver, and 865 patients (27.5%) showed signs of disease on imaging examination. The majority of these cases had spread by the middle of the second year after the first diagnosis of colorectal cancer. These data suggest that routine imaging tests of the liver should be included in the treatment for patients with colorectal cancer.